Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Buy ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

KLP Kapitalforvaltning AS bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the fourth quarter, ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

American Century Companies Inc. lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.6% in the 4th ...

In a report released on March 10, Anupam Rama from J.P. Morgan maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price target of $44.00. The company’s shares closed ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Buy recommendation. As of March 19, 2025, the average one-year price target ...

Piper Sandler analyst Biren Amin maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price target of $46.00.

On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in the sector. He said that looking at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well as royalties in the low double digits on sales of acoramidis in Japan, with ...